RCM
ITRM

Riverhead Capital Management’s Iterum Therapeutics ITRM Stock Holding History

Riverhead Capital Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$7K Hold
78
– – ﹤0.01% 1495
2019
Q2 		$8K Sell
78
-2
-3% -$222 ﹤0.01% 1513
2019
Q1 		$10K Sell
80
-416
-84% -$38.2K ﹤0.01% 1485
2018
Q4 		$37K Hold
496
– – ﹤0.01% 1445
2018
Q3 		$50K Sell
496
-7
-1% -$914 ﹤0.01% 1491
2018
Q2 		$82K Buy
+503
New +$90.8K ﹤0.01% 1391

Other funds holding ITRM

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return

Riverhead Capital Management's ITRM Position: Q3 2019 in Review

Riverhead Capital Management held its Iterum Therapeutics (ITRM) position steady in Q3 2019 at 78 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1495.

Riverhead Capital Management first reported a position in ITRM in Q2 2018 and has held it in 6 quarters since. The position peaked at $82K in Q2 2018. 19 funds tracked by Wall St. Rank hold ITRM as of Q3 2019.

  • Riverhead Capital Management held 78 shares of Iterum Therapeutics worth $7K as of Q3 2019.
  • Riverhead Capital Management left its Iterum Therapeutics share count unchanged in Q3 2019.
  • Iterum Therapeutics made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1495 holding.
  • Riverhead Capital Management first reported a position in Iterum Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Riverhead Capital Management's Iterum Therapeutics position peaked at $82K in Q2 2018.
  • 19 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.